Samaritan Pharmaceuticals, Inc. (AMEX: LIV)

Dear Reader, 

At StockUpTicks we’ve been brazen in our pronounced affinity and affection for biotechnology based companies. But while that exuberance is unbridled for the industry and all the positive events heretofore, we are not ready to paint all biotech companies with the same benevolent brush.

Instead, we endeavor to identify companies with unique and potent technology honed in the FDA approval process and whenever possible, endorsed by their affiliation with leading research laboratories, often in the academic setting.  This, we have found, is quite often a component and pre-cursor to success as a company and eventually as an equity.

With this in mind, we feel fortunate to have ‘discovered,’ if you will, a company that appears to embody the aforementioned values.  It had been brought to our attention by a respected stockbroker who understands biotech better than any we’ve ever met.  We now feel ready to showcase this intriguing biotechnology firm of 250 drug candidates in fields ranging from Alzheimer's, Aids, Cancer and Heart Disease to you, our dear reader.

Biotech can be a tough read but we’d like to think we’ve broken the story down into digestible components so that you too can see what we find compelling about this equity.  We kindly suggest you take a moment to review the profile below.
>>

About Samaritan

Samaritan Pharmaceuticals, Inc. (AMEX:LIV) is a drug development company driven to discover, develop and commercialize new, innovative drugs for AIDS, Alzheimer’s, Cancer and Heart disease.  Samaritan is currently advancing eight promising compounds out of its rich pipeline of 250 possible drug candidates, all of which have the potential to create revenue-generating opportunities. In addition, the majority of Samaritan’s patented drugs are credentialed with peer-reviewed journals and some with National Institutes of Health ( NIH) grants. 

Drug Development 
HIV Phase IIb/III Drug Program: Samaritan is currently developing SP-01A through PIIb/III  pivotal clinical human trials for HIV drug resistant patients who are failing triple therapy. 

Alzheimer's Drug Program:  Samaritan has accomplished all the preclinical trials necessary to file for an IND for its Alzheimer's drug SP-233. 

Samaritan Corporate
Samaritan’s business offices are located in Las Vegas, Nevada. The main business of the  corporate office is drug development and business development; with research and discovery, taking place at Samaritan Laboratories, Georgetown University, Washington, D.C.  Samaritan Corporate focuses on accomplishing the pre-clinicals required to file for Investigational New Drug applications, (IND's), Food and Drug Administration (FDA) Human  Clinical  Trials and everything necessary to get drug candidates regulatory approval.  Its strategy is to partner most of its drug candidates with major pharmaceuticals, except for the ones that it can financially carry alone.
 

Samaritan Drug Candidate Pipeline

The Stars of the Pipeline

AIDS/HIV:
SP-01A is an oral entry inhibitor, CCR5, attachment inhibitor.  Although, SP-01A is the lead HIV drug, preclinical studies for SP10 and SP03 have suggested similar characteristics.

Phase IIb Monotherapy Study:
Samaritan is currently conducting a new “Multi-Center Double-Blind, Randomized, Placebo-Controlled Study of Orally Administered SP01A as Monotherapy Treatment of HIV-Infected Patients” Phase II trial that will demonstrate efficacy as an antiviral and allow us to gather dosage data.

Phase I/II Study: 
The safety and dose response of orally administered SP-01A  in HIV infected patients was assessed in this study.  SP-01A demonstrated proof of concept with significance in two crucial areas, viral load and improvement in quality of life. The inhibitory effect of SP-01A on the entry of HIV and multi-drug resistant HIV viral strains reinforced our conviction that it targets the host cell, rather than the virus itself, rendering SP-01A less susceptible to emerging resistances than any other drugs on the market.

Samaritan’s Alzheimer’s technology features four promising therapeutics (SP-04, SP-04m, SP-08 and SP-233); two neural stem cell differentiation therapies (SP-sc4 and SP-sc7), a predictive diagnostic and an Alzheimer’s animal model to test new drugs.

Stem Cell Therapy (Non-Embryonic) SP-4: Neural Cell Growth and Differentiation: Samaritan has shown that it’s neuronal stem cell therapy drugs (SP-sc4 and SP-sc7) can induce dormant brain neuronal stem cells to differentiate rapidly into adult neuron cells as a novel treatment for Alzheimer's disease and other neurodegenerative disorders.  Samaritan has received an NIH grant to further develop this technology.

Alzheimer’s Drug SP-233: Samaritan’s preclinical trials suggest Alzheimer’s disease therapy, SP-233, has the ability to protect neurons against beta-amyloid-induced toxicity.  It was shown to bind to the beta-amyloid peptide, to prevent its oligomerization and entry into neurons, to protect neuronal mitochondria from beta-amyloid-induced damage and to maintain neuronal cell energy levels. 

Alzheimer’s Predictive Diagnostic:  Samaritan has found that the central nervous system’s DHEA is increased in patients having Alzheimer’s, contradicting previous reports alleging DHEA levels in Alzheimer’s patients are abnormally low.  This research has been the basis of Samaritan’s Alzheimer’s diagnostic test and the granting of research funds from the National Institutes of Health.  Advantage: The Alzheimer’s diagnostic is a simple blood test, exceedingly superior to the invasive spinal taps or expensive MRIs currently used by competitors. Samaritan has received an NIH grant to further develop this technology.

Alzheimer’s Animal (Rat) Model: Samaritan has developed an animal model that mimics the human phenotype of Alzheimer’s disease pathology and is used to test the efficacy of new Alzheimer's medications.  Samaritan has used this animal model to test its own Alzheimer's drugs and expects to out-license this technology to other pharmaceutical Companies to do the same.

AIDS/HIV Program SP-01A Inhibitor, Click Here SP-10 HIV, Click Here

CNS - Alzheimer's Program SP-233 Alzheimer's Drug, Click Here Alzheimer's Stem Cell, Click Here Cardiovascular:  Click Here

Samaritan Europe Samaritan Pharmaceuticals Europe (SPE) provides access to the markets of Eastern Europe, Asia and Africa where there is a high proportion of HIV.  In addition, SPE plans to develop Samaritan's pipeline of drugs through clinical trials to obtain European approval; which upon approval, would then be responsible for the marketing and sales of such approved drugs in the under serviced regions of  Central and Southeast Europe.

Samaritan Ireland - Manufacturing SPE Sales & Marketing: SPE is currently building sales and marketing infrastructure.  SPE is in-licensing niche products to market and sell pharmaceutical products in the usually neglected regions of Central and Southeast Europe.  Although small to begin with, it will be a source of revenue for Samaritan until one of its drugs is partnered. Manufacturing: SPE and Pharmaplaz LTD in Ireland have established a manufacturing arrangement to meet regulatory requirements, clinical trials supplies and future production needs.  In addition, SPE intends to collaborate with a European university to take advantage of funding opportunities with applicable European grants.

European Sales & Marketing
Amphocil®
An In-Licensed Drug

Amphocil® Amphotec® (amphotericin B cholesteryl sulfate complex for injection), also marketed under the name Amphocil®, is a lipid-form of amphotericin B indicated for the treatment of invasive aspergillosis in patients where renal impairment or unacceptable toxicity precludes the use of amphotericin B deoxycholate in effective doses, and in patients with invasive aspergillosis where prior amphotericin B deoxycholate has failed.

Recent News From Samaritan

LAS VEGAS--(BUSINESS WIRE)--March 9, 2006--Samaritan Pharmaceuticals Inc. (AMEX:LIV - News) a developer of innovative drugs, announced today, it is starting a second Phase II monotherapy trial, of its lead oral entry inhibitor anti-viral agent SP01A, in treatment experienced HIV-infected patients.

Dr. Thomas Lang, Samaritan's Chief Drug Development Officer stated, "We have completed enrollment for our first monotherapy trial and the start of this second trial means we have cleared another important milestone in SP01A's development path."

Dr. Janet Greeson, CEO of Samaritan stated, "We remain enthusiastically confident in the promise of SP01A. As we successful complete each of these FDA milestones, it completely strengthens our belief in SP01A as a life-saving drug for HIV drug resistant patients."

To read the complete release and disclaimer, Click Here

Press Release Source: Samaritan Pharmaceuticals Inc. 
Wednesday March 1, 8:00 am ET 

LAS VEGAS--(BUSINESS WIRE)--March 1, 2006--Samaritan Pharmaceuticals, Inc. (AMEX:LIV - News), a developer of innovative drugs, announced today the welcoming of Dr. Pauline S. Nys, a distinguished leader and innovator in the field of anticancer and cardiovascular drug development, to its Scientific Advisory board.

Dr. Nys was a Full Professor of Biotechnology at the Research Center for Antibiotics, in Moscow, Russia. Presently, she serves as a Scientific Advisor to a few European and US biotechnological companies. Dr. Nys has published more than 100 articles in international scientific journals, as well as presenting numerous professional papers at scientific meetings. In addition, she is the author of more than 25 patents for biologically active compound production.

To read the complete release and disclaimer, Click Here

Press Release Source: Samaritan Pharmaceuticals, Inc. 
Tuesday February 28, 8:00 am ET 

LAS VEGAS--(BUSINESS WIRE)--Feb. 28, 2006--Samaritan Pharmaceuticals Inc. (AMEX:LIV - News), a developer of innovative drugs, announced today it has received its unique CAS Registry Number for the chemical substance in its Alzheimer's drug SP-233. CAS Registry Numbers are used in reference works, databases, and regulatory compliance documents, to identify substances without the ambiguity of chemical nomenclature. 

Substance ID:     Caprospinol
CAS No.:          873956-96-8

Dr. Greeson, CEO of Samaritan Pharmaceuticals, stated, "We are completely excited about SP-233 (Caprospinol) as a totally new approach to treat Alzheimer's disease." Dr. Greeson continued, "We have been aggressively pushing to file an investigational new drug (IND) application for Caprospinol and this is one of the many milestones we have had to achieve to get there." 

To read the complete release and disclaimer, Click Here
a

Press Release Source: Samaritan Pharmaceuticals Inc. 
Tuesday February 21, 7:00 am ET 

LAS VEGAS--(BUSINESS WIRE)--Feb. 21, 2006--Samaritan Pharmaceuticals Inc. (AMEX:LIV - News): Lead Discovery in Announcing Breaking Journal Articles Features Neuroscience Article Discussing the Spirostenol Compound SP-233 to Be Of Special Interest.

• Samaritan Has In-Licensed Cited Alzheimer's Drug SP-233
• Preclinical Trials Continue to Show Promise
• Expect to File for Alzheimer's IND with FDA Mid-Year

Georgetown University has exclusively licensed the spirostenol derivative SP-233 to Samaritan Pharmaceuticals. Samaritan expects SP233 to be its first Alzheimer's application to the FDA, Investigational New Drug (IND), and expects to file by mid-year. 

To read the complete release and disclaimer, Click Here

LAS VEGAS--(BUSINESS WIRE)--Feb. 2, 2006--Samaritan Pharmaceuticals Inc. (AMEX:LIV - News) a developer of innovative drugs, announced today, it has agreed to exclusively license "Use of Spirostenols to treat Mitochondrial Disorders" from Georgetown University.

Mitochondria are specialized compartments present in every cell of the body, except red blood cells and are responsible for generating over 90% of the energy needed to sustain life. Diseases thought to involve mitochondria impairment are Alzheimer's, Parkinson's, Multiple Sclerosis, and conditions such as, neuronal death induced by stroke, traumatic brain injury, seizures and spinal cord injury, among many others.

Dr. Janet Greeson, CEO of Samaritan Pharmaceuticals stated, "We are extremely pleased with our collaboration with Georgetown University, it gives us the ability to continually, build and grow, our pipeline of innovative drugs. The future, and our future, is dependent on innovation, and I feel 100% confident our shareholders will be kindly rewarded for being patient with us as we build and grow Samaritan."

To read the complete release and disclaimer, Click Here
a

The Samaritan Executive Management Team

aaa

Dr. Janet Greeson - Chief Executive Officer, President and Director  Dr. Janet Greeson, Chairman, President and CEO, led the bold initiative that transformed Samaritan from a "one drug" Company to an innovative "Drug Development Pipeline" Biopharmaceutical Company. She strategically created a long-term value and growth model, with the Samaritan/Georgetown University collaboration; and intends to duplicate this growth model with other top tier Universities, as a solid strategy to continually build Samaritan's value and sustain its future profitability. Dr. Greeson is a successful healthcare professional with over two decades of corporate experience focused on emerging growth situations, leadership development, and mergers and acquisitions. Although she has worked with Samaritan for nine years, as CEO for the past four years she has demonstrated a relentless perseverance and determination to succeed in the face of unrelenting change. She is extremely motivated and equipped to attack problems and seize realistic opportunities, with capability, courage and confidence. Dr. Greeson is a co-inventor of 18 patent applications, and presently has nine "peer reviewed" journal publications. She is a best selling author of "It's Not What You Are Eating, It's What's Eating You"; and a renowned public speaker, whose guest appearances on numerous radio and TV Talk shows, has opened the door to tell the Samaritan story, in a concise and professional manner. Dr. Greeson is an experienced growth "Model" developer. In the past, Dr. Greeson developed model "Addiction Rehab Programs" for the US Navy, and went on privately, to develop and grow a nationwide "inpatient treatment program model" which she later sold to Columbia/HCA (NYSE:COL). Dr. Greeson has an eclectic past, once working with Mother Theresa and was privileged to be the U.S. Congressional Nominee for the State of Nevada in 1994, winning the primary without spending a dollar to campaign. She currently fulfills her altruistic energies with the Samaritan Innovative Science Foundation. Dr. Greeson holds a BA, from Florida Technological University 1978; an MA from Rollins College 1979; a PhD from Columbia Pacific University 1987. Dr. Greeson devotes substantially all of her time to the affairs of Samaritan Pharmaceuticals.

Eugene J. Boyle - Chief Financial Officer, Chief Operating Officer, Director Eugene Boyle is the Chief Financial Officer, Chief Operations Officer, and a Director of Samaritan Pharmaceuticals. Mr. Boyle received a B.S.E. in Computer Engineering and Applied Mathematics from Tulane University, served in the US Navy as a Lt. during the Gulf War and then went on to get his M.B.A. from Babson College and J.D. from Concord University. Mr. Boyle is a registered patent agent and admitted to practice before the United States Patent and Trademark Office (USPTO) in all matters relating to patents. He has extensive experience in all aspects of innovation and technology transfer. He has passed the first of three yearly exams to be classified as a Charted Financial Analyst(CFA), as well as the series 7 and 63 securities brokerage registered representative exams, although he is not a practicing representative. He also served on Nevada Gold & Casino's (AMEX:UWN) Advisory Board from 1999 to 2003.

Dr. Thomas Lang Ph.D., Chief Drug Development Officer  As the CEO and President of Strategic Development Consulting and the former Vice Chairman and President of Serono Inc., (the US Company of Serono, S.A., the world's third largest biotech company), Dr. Lang is a highly regarded senior executive with over twenty-five years of experience in the pharmaceutical and biotech industry. Dr. Lang holds technical degrees in Chemistry and Pharmacy, an MBA degree, a Ph.D. degree, and is a registered pharmacist in the State of New Jersey. Prior to founding Strategic Development Consulting, Mr. Lang had a very successful career with such companies as Ciba-Geigy, Janssen, Warner-Lambert, Organon, and, most recently, Serono. After joining Serono in 1995, Dr. Lang held increasingly senior executive level positions within Serono while successfully guiding the company's short and long-term tactical and strategic planning for overall product development and commercialization of its traditional and advanced biotech products in the therapeutic areas of Fertility, Growth, Metabolism & Immunology, and Multiple Sclerosis in the US. This has lead to the commercialization of seven products (5 of which were recombinant products), which currently account for more than 95% of the company's sales.

Mr. George Weaver, Regulatory Affairs Officer  Mr. Weaver majored in chemistry, minored in business economics, and was one of a select group of students to successfully petition UCLA and participate in an accelerated Pre-Medicine/Medicine program. After working as an environmental toxicology consultant for two years, Mr. Weaver earned a Bachelor's of Science in Environmental Engineering and assumed an appointed position as Chair of Industry Waste Classification and Toxicology Focus Group under the California Department of Toxic Substances Control Regulatory Structure Update. Mr. Weaver also worked for and under contract with the United States Navy Public Works Center. Mr. Weaver is responsible for several environmental and toxicological advances within the Department of Defense including a notable contribution to the DOD Uniform National Discharge Standards (UNDS) guidelines created jointly with the United States Environmental Protection Agency and the US Coast Guard; development of the Navy's toxicological profile guidelines for hazardous materials and wastes in San Diego; and significant contribution to the development of DOD radiological, biohazardous, and infectious materials permitting guidelines.

Kristi Eads, Vice President of Investor Relations and Corporate Secretary Kristi Eads, Vice President of Investor Relations joined Samaritan Pharmaceuticals in 2000, and has functioned as Vice President of Investor Relations since January of 2004. Ms. Eads oversees all communications with the investment community, public and private. Ms. Eads brings with her a diverse experience in investor and corporate relations, accounting and marketing. Prior to joining Samaritan, Ms. Eads work related experience in advertising, banking and the political arena has enhanced her overall ability to communicate the Samaritan story. Ms. Eads has a Bachelor of Arts from the University of Oregon, and is a Juris Doctorate Degree candidate with Concord University.

Financial Highlights For Samaritan

Sector: Healthcare  Industry: Biotechnology MEMBER AMEX COMPOSITE INDEX (AMEX: ^XAX)  AMEX HEALTHCARE SUB INDEX (^XHL) Last Trade: $0.32 (03-14-06) Market Cap: $42.32M  52wk Range: $0.31 - $0.92 Fiscal Year Ends: 31-Dec  Most Recent Qtr : 30-Sep-05  Income Revenue (ttm): $135.43K  Total Cash (mrq): $1.60M  State of Incorporation: NV

Transfer Agent: Securities Transfer Corporation

TO CONTACT SAMARITAN  (AMEX: LIV)

---

*** The Bull is Running. ***
There may never be a better time to feature YOUR company
to over 1 MILLION investors.

To learn more about our programs email us directly at info@stockupticks.com

Disclaimer: StockUpTicks.com is a property of Market Pathways Financial Relations Incorporated (MP).  The information, opinions and analysis contained herein are based on sources believed to be reliable but no representation, expressed or implied, is made as to its accuracy, completeness or correctness.  Past performance is no guarantee of future results. This report is a paid advertisement and is for information purposes only and should not be used as the basis for any investment decision.  MP has been paid five thousand dollars by Samaritan Pharmaceuticals for preparation and distribution of this report and other advertising services over a thirty day period.  This constitutes a conflict of interest as to MP’s ability to remain objective in its communication regarding the subject company.  Write or call MP for detailed disclosure as required by Rule 17b of the Securities Act of 1933/1934 - Market Pathways 17595 Harvard Ave., Suite C519 Irvine, CA  92614.  MP is not an investment advisor and this report is not investment advice. This information is neither a solicitation to buy nor an offer to sell securities but is a paid advertisement.  Information contained herein contains forward-looking statements and is subject to significant risks and uncertainties, which will affect the results.  The opinions contained herein reflect our current judgment and are subject to change without notice. MP and/or its affiliates, associates and employees from time to time may have either a long or short position in securities mentioned.  Information contained herein may not be reproduced in whole or in part without the express written consent of Market Pathways Financial Relations Incorporated.